Development of β-secretase Inhibitor as Drug for Alzheimerûs Disease
Article Sidebar
Main Article Content
Abstract
No Abstract
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Asai M, Hattori C, Iwata N, et al. 2006. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96 (2): 533-540.
Asberom T, Bara TA, Clader JW, et al. 2007. Tetra hydroquinoline sulfonamides as gamma- secretase inhibitors. Bioorg Med Chem Lett 17(1): 205-207.
Best JD, Jay MT, Otu F, Churcher I, et al. 2006. In vivo characterization of Abeta (40) changes in brain and cerebrospinal fluid usingn the novel gamma-secretaseinhibitor N-[cis-4-[(4- chlorophenyl) sulfonyl]-4-(2,5-difluoro- phenyl) cyclohexyl]-1,1, 1-trifluoromethane- sulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 317(2): 786-790.
Best JD, Jay MT, Otu F, et al. 2005. Quantitative measurement of changes in amyloid-beta (40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluoro- phenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl- 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]- L-alaninamide]. J Pharmacol Exp Ther 313(2): 902-908.
Best JD, Smith DW, Reilly MA, et al. 2007. The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl) sulfonyl]-4-(2,5-difluoro phenyl) cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320(2): 552-558.
Citron M. 2004. Strategies for disease modification in Alzheimerûs disease. Nat Rev Neurosci 5(9):677-685.
Citron, M. 2002. Emerging Alzheimerûs disease therapies: inhibition of β-secretase. Neurobiol Aging 23(6): 1017-1022.
Fassa A, Parisiadou L, Robakis NK, et al. 2007. Novel processing of Notch 1 within its intracellular domain by a cysteine protease. Neurodegener Dis 4(2-3): 148-155.
Findeis, M. A. 2007. The role of amyloid beta peptide 42 in Alzheimerûs disease. Pharmacol Ther 116(2): 266-286.
Freskos JN, Fobian YM, Benson TE, et al. 2007a. Design of potent inhibitors of human beta-secretase. Part 1. Bioorg Med Chem Lett 17(1): 73-77.
Freskos JN, Fobian YM, Benson TE, et al. 2007b. Design of potent inhibitors of human beta-secretase. Part 2. Bioorg Med Chem Lett 17(1): 78-81.
Hamada Y, Igawa N, Ikari H, et al. 2006. Beta-Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 16(16): 4354- 4359.
Higuchi M, Iwata N, Saido TC. 2005. Understanding molecular mechanisms of proteolysis in Alzheimerûs disease: Progress toward therapeutic interventions. Biochim Biophys Acta 1751(1): 60-67.
http://www.web-books.com/eLibrary/Medicine/Neurological/Alzheimer_Tau.htm
Hyde LA, McHugh NA, Chen J, et al. 2006. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2- (3,5-difluorophenyl)-2-hydroxyethanoyl]-N1- [(7S)-5-methyl-6-oxo-6,7-dihydro-5H- dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther 319(3): 1133-1143.
Lindsley SR, Moore KP, Rajapakse HA, et al. 2007. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 17(14): 4057-4061.
Maillard MC, Hom RK, Benson TE, et al. 2007. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 50(4): 776-781.
Mancini F, Naldi M, Cavrini V, et al. 2007. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 388(5-6): 1175- 1183.
Mandel S, Weinreb O, Amit T, et al. 2005. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48(2): 379-387.
Pietrak BL, Crouthamel MC, Tugusheva K, et al. 2005. Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal Biochem 342(1): 144-151.
Rajapakse HA, Nantermet PG, Selnick HG, 2006. D iscovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 49(25): 7270-7273.
Rojo I, Martin JA, Broughton H, et al. 2006. Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. Bioorg Med Chem Lett 16(1): 191-195.
Takahashi Y, Fuwa H, Kaneko A, et al. 2006. Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett 16(14): 3813-3816.
Takeshita K, Satoh M, Ii M, et al. 2007. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 100(1): 70-78.
Yeon SW, Jeon YJ, Hwang EM, et al. 2007. Effects of peptides derived from BACE1 catalytic domain on APP processing. Peptides 28(4): 838-844.